Julien Braux

Dr. Julien Braux

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2011 in Acta Biomaterialia
Verified
Journal Article
Closed access
JBJulien Braux
Julien Braux
Frédéric VelardFrédéric Velard
Frédéric Velard
CGChristine Guillaume
Christine Guillaume
SBSylvie Bouthors
Sylvie Bouthors
EJEdouard Jallot
Edouard Jallot
PLPatrice Laquerrière
Patrice Laquerrière

21 January 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
MDMarie Dubus
Marie Dubus
LSloïc scomazzon
loïc scomazzon
JCJulie Chevrier
Julie Chevrier
CLCharlotte Ledouble
Charlotte Ledouble
ABAdrien Baldit
Adrien Baldit
HKHalima Kerdjoudj
Halima Kerdjoudj
Of all biologic matrices, decellularized tissues have emerged as a promising tool in the field of regenerative medicine. Few empirical clinical studies have shown that Wharton’s jelly (WJ) of the human umbilical cord promotes wound closure and reduces wound-related infections. In this scope, we herein investigated whether decellularized (DC)-WJ could be used as an engineered biomaterial. In comparison with devitalized (DV)-WJ, our results showed an inherent effect of DC-WJ on Gram positive (S. aureus and S. epidermidis) and Gram negative (E. coli and P. aeruginosa) growth and adhesion. Although DC-WJ activated the neutrophils and monocytes in a comparable magnitude to DV-WJ, macrophages modulated their phenotypes and polarization states from the resting M0 phenotype to the hybrid M1/M2 phenotype in the presence of DC-WJ. M1 phenotype was predominant in the presence of DV-WJ. Finally, the subcutaneous implantation of DC-WJ showed total resorption after three weeks of implantation without any sign of foreign body reaction. These significant data shed light on the potential regenerative application of DC-WJ in providing a suitable biomaterial for tissue regenerative medicine and an ideal strategy to prevent wound-associated infections.

15 February 2018 in Journal of Clinical Periodontology
Verified
Journal Article
Closed access
PDF file
MJMarie‐Laure Jourdain
Marie‐Laure Jourdain
LPLoïc Pierrard
Loïc Pierrard
LKLukshe Kanagaratnam
Lukshe Kanagaratnam
Frédéric VelardFrédéric Velard
Frédéric Velard
JSJohan Sergheraert
Johan Sergheraert
JBJulien Braux
Julien Braux

Verified
Journal Article
Open access
PDF file
AMAurélie Moniot
Aurélie Moniot
JBJulien Braux
Julien Braux
RSRenaud SIBONI
Renaud SIBONI
CGChristine Guillaume
Christine Guillaume
SASandra AUDONNET
Sandra AUDONNET
Frédéric VelardFrédéric Velard
Frédéric Velard
In inflammatory diseases, polymorphonuclear neutrophils (PMNs) are known to produce elevated levels of pro-inflammatory cytokines and proteases. To limit ensuing exacerbated cell responses and tissue damage, novel therapeutic agents are sought. 4aa and 4ba, two pyridazinone-scaffold-based phosphodiesterase-IV inhibitors are compared in vitro to zardaverine for their ability to: (1) modulate production of pro-inflammatory mediators, reactive oxygen species (ROS), and phagocytosis; (2) modulate degranulation by PMNs after transepithelial lung migration. Compound 4ba and zardaverine were tested in vivo for their ability to limit tissue recruitment of PMNs in a murine air pouch model. In vitro treatment of lipopolysaccharide-stimulated PMNs with compounds 4aa and 4ba inhibited the release of interleukin-8, tumor necrosis factor-α, and matrix metalloproteinase-9. PMNs phagocytic ability, but not ROS production, was reduced following treatment. Using a lung inflammation model, we proved that PMNs transmigration led to reduced expression of the CD16 phagocytic receptor, which was significantly blunted after treatment with compound 4ba or zardaverine. Using the murine air pouch model, LPS-induced PMNs recruitment was significantly decreased upon addition of compound 4ba or zardaverine. Our data suggest that new pyridazinone derivatives have therapeutic potential in inflammatory diseases by limiting tissue recruitment and activation of PMNs.

14 September 2022 in Cells
Verified
Journal Article
Open access
PDF file
MDMarie Dubus
Marie Dubus
LSloïc scomazzon
loïc scomazzon
CLCharlotte Ledouble
Charlotte Ledouble
JBJulien Braux
Julien Braux
ABAbdelilah Beljebbar
Abdelilah Beljebbar
HKHalima Kerdjoudj
Halima Kerdjoudj
In craniofacial bone defects, the promotion of bone volume augmentation remains a challenge. Finding strategies for bone regeneration such as combining resorbable minerals with organic polymers would contribute to solving the bone volume roadblock. Here, dicalcium phosphate dihydrate, chitosan and hyaluronic acid were used to functionalize a bone-side collagen membrane. Despite an increase in the release of inflammatory mediators by human circulating monocytes, the in vivo implantation of the functionalized membrane allowed the repair of a critical-sized defect in a calvaria rat model with de novo bone exhibiting physiological matrix composition and structural organization. Microtomography, histological and Raman analysis combined with nanoindentation testing revealed an increase in bone volume in the presence of the functionalized membrane and the formation of woven bone after eight weeks of implantation; these data showed the potential of dicalcium phosphate dihydrate, chitosan and hyaluronic acid to induce an efficient repair of critical-sized bone defects and establish the importance of thorough multi-scale characterization in assessing biomaterial outcomes in animal models.

4 October 2023 in Materials Today Bio
Verified
Journal Article
Open access
LTL. Thoraval
L. Thoraval
ETE. Thiébault
E. Thiébault
RSRenaud SIBONI
Renaud SIBONI
AMAurélie Moniot
Aurélie Moniot
CGC. Guillaume
C. Guillaume
Frédéric VelardFrédéric Velard
Frédéric Velard
Infection and inflammation are two key features to consider to avoid septic or aseptic loosening of bone-implanted biomaterials. In this context, various approaches to fine-tune the biomaterial's properties have been studied in order to modulate the crosstalk between immune and skeletal cells. Cation-doping strategies for tuning of calcium phosphates properties has been evidenced as a promising way to control the biomaterial-induced inflammatory process, and thus improving their osteoimmunomodulatory properties. Copper(II) ions are recognized for their antibacterial potential, but the literature on their impact on particulate material-induced acute inflammation is scarce. We synthesized copper(II) ions-doped biphasic calcium phosphate (BCP), intended to exhibit osteoimmunomodulatory properties. We addressed in vitro, for the first time, the inflammatory response of human primary polymorphonuclear neutrophils (PMNs) to copper(II) ions-doped or undoped (BCP) powders, synthesized by an original and robust wet method, in the presence or absence of LPS as a costimulant to mimic an infectious environment. ELISA and zymography allowed us to evidence, in vitro, a specific increase in IL-8 and GRO-α secretion but not MIP-1β, TNF-α, or MMP-9, by PMNs. To assess in vivo relevance of these findings, we used a mouse air pouch model. Thanks to flow cytometry analysis, we highlighted an increased PMN recruitment with the copper(II) ions-doped samples compared to undoped samples. The immunomodulatory effect of copper(II) ions-doped BCP powders and the consequent induced moderate level of inflammation may promote bacterial clearance by PMNs in addition to the antimicrobial potential of the material. Copper(II) doping provides new insights into calcium phosphate (CaP)-based biomaterials for prosthesis coating or bone reconstruction by effectively modulating the inflammatory environment.